Quantcast

Latest Vion Pharmaceuticals, Inc. Stories

2011-06-07 15:05:00

PALO ALTO, Calif., June 7, 2011 /PRNewswire/ -- Telik, Inc. (Nasdaq: TELK) today announced the initiation of a Phase 2 clinical trial to evaluate oral Telintra in patients with Revlimid refractory or resistant, deletion 5q myelodysplastic syndrome (del 5q MDS). This is a multicenter trial intended to enroll up to 117 evaluable patients. It employs a sequential design with two interim analyses. These patients are transfusion dependent with Low to Intermediate-1 Risk MDS. Telintra will be...

2010-06-21 13:33:00

PALO ALTO, Calif., June 21 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK) today announced the publication of a case report by Quddus et al., Oral Ezatiostat HCl (Telintra) and Myelodysplastic Syndrome: A case report of sustained hematologic response following an abbreviated exposure. Journal of Hematology & Oncology 2010, 3:16. This case report describes a patient who experienced a sustained hematologic response in all three blood cell lines continuing for over a year, after an...

2010-02-26 15:00:00

NEW HAVEN, Conn., Feb. 26 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (OTC Bulletin Board: VIONQ) announced today that it had received a response from the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment ("SPA") for its oncology therapeutic Onrigin(TM) (laromustine) Injection. In January 2010, Vion filed a SPA with the FDA related to a randomized Phase II/III trial of Onrigin(TM) in combination with low-dose Ara-C (LDAC) in elderly patients with newly...

2010-01-25 07:00:00

NEW HAVEN, Conn., Jan. 25 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. issued a management statement related to the continuing trading volume in the Company's common stock. Management informed investors that it had noticed continuing high trading volume in the Company's common stock after the Company's filing for bankruptcy and of its belief that there will be no value for the common stockholders in the Company's bankruptcy liquidation process, even under the most optimistic of...

2010-01-12 07:00:00

NEW HAVEN, Conn., Jan. 12 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (OTC Bulletin Board: VION) announced today that it had filed a Special Protocol Assessment (SPA) with the U.S. Food and Drug Administration (FDA) related to a randomized Phase II/III trial of its oncology therapeutic Onrigin(TM) (laromustine) Injection in combination with low-dose Ara-C (LDAC) in elderly patients with newly diagnosed acute myeloid leukemia (AML). The primary objective for the Phase III part of...

2009-12-30 07:00:00

NEW HAVEN, Conn., Dec. 30 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (OTC Bulletin Board: VION), announced today that the U.S. Food and Drug Administration ("FDA") had responded to its Special Protocol Assessment ("SPA") request to evaluate the Phase III randomized trial HOVON AML 92 sponsored by the Dutch-Belgian Cooperative Group for Hematology Oncology ("HOVON") of its lead product Onrigin(TM). The FDA raised concerns with the HOVON trial design as submitted regarding the...

2009-12-17 14:35:00

NEW HAVEN, Conn., Dec. 17 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (OTC Bulletin Board: VION), a pharmaceutical company focused on the development of novel cancer therapeutics, announced that it had voluntarily filed for bankruptcy under Chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware. Vion is continuing to operate its business as a debtor-in-possession pursuant to Sections 1107 and 1108 of the Bankruptcy...


Word of the Day
mundungus
  • A stinking tobacco.
  • Offal; waste animal product; organic matter unfit for consumption.
This word comes from the Spanish 'mondongo,' tripe, entrails.